Mary Grecco

DocwireNews

Among patients with advanced/metastatic non-small cell lung cancer (NSCLC), first-line immunotherapy significantly improves survival; the anti-PD-1 antibody pembrolizumab alone has shown superior efficacy over chemotherapy in untreated patients with advanced NSCLC and PD-L1 expression &sup3;50%. However, most patients will eventually experience progression.The phase 1 TROPION-PanTumor01 study showed that monotherapy with datopotamab deruxtecan (Dato-DXd), an antibody-drug conjugate composed of a humanized anti-TROP IgG1 monoclonal antibody covalently linked to a topoisomerase I inhibitor, demonstrated an objective response rate (ORR) of 28% and a tolerable safety profile in pretreated patients with NSCLC. Subsequently, the phase 1b trial evaluated Dato-DXd combined with pembrolizumab and showed a preliminary ORR of 62% and a disease control rate of 100%. The most frequent treatment-emergent adverse events were stomatitis and nausea.The details of TROPION-Lung08, a phase 3, global, randomized, open-label, active-controlled trial, were presented at WCLC 2023 in Singapore. The trial is now enrolling approximately 740 patients to evaluate the efficacy and safety of Dato-DXd plus pembrolizumab versus pembrolizumab alone in treatment-na&iuml;ve patients with advanced/metastatic NSCLC without actionable genomic alterations and PD-L1 expression &sup3;50%. Patients will be randomized 1:1 to receive Dato-DXd 6 mg/kg plus pembrolizumab 200 mg or pembrolizumab 200 mg alone via infusion every 21 days until disease progression, discontinuation, or 35 cycles of pembrolizumab.The primary end points of the study will include progression-free survival (PFS) and overall survival; secondary end points will include ORR, investigator-assessed PFS, PFS2, duration of response, time to response, disease control rate, time to deterioration, safety, and antidrug antibody prevalence. Pharmacokinetic parameters, biomarkers, and patient-reported outcomes will also be explored.Source: Zhou C, Levy BP, Sands J, et al. TROPION-Lung08: Datopotamab deruxtecan plus pembrolizumab in untreated advanced/metastatic non-small cell lung cancer (NSCLC). Abstract of a poster presented at the 2023 World Conference on Lung Cancer; September 9-12, 2023; Singapore.

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Datopotamab Deruxtecan Plus Pembrolizumab in Patients With Untreated Advanced/ Metastatic NSCLC

WCLC 2023

A study showed that monotherapy with datopotamab deruxtecan is safe and effective in pretreated patients with NSCLC.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe